FPSIR predicts clinical therapeutic responses and survival outcomes in patients with metastatic colorectal cancer undergoing first-line bevacizumab-containing chemotherapy. - Li YN; Deng FW; Lan TQ; Lu Y; Xiang L; Song GB; Peng T; Cheng XX; Ying HQ (Frontiers in immunology, 2026)